Adlai Nortye Ltd.(NASDAQ:ANL) 
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent ...
Website: https://www.adlainortye.com/
Founded: 2004
IPO Price: $23 (Sep 29, 2023)
Sector: TECHNOLOGY
Industry: GENERAL
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 2.03
H 2.06
L 1.96
C 1.96
V 12,421
10EMA 1.96
20EMA 1.96
60EMA 1.96
120EMA 1.96
250EMA 1.96